TWST Twist Bioscience Corporation
USHealthcareAs of 2026-07-10 16:00
Why TWST matters now
Twist Bioscience Corporation (TWST) is a US stock in Healthcare. The latest InvestLog snapshot shows $90.64 with -3.24% on the session and $5.64B in market capitalization; recent performance reads 1-month +76.89% and YTD +176.04%.
The latest financial table shown here is Q2 2026, with revenue of $110.7M, net income of $-44.0M, and EPS of $-0.71. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1.7%.
The latest indexable market news headline is "Ozempic Linked To Lower Risk Of Violence In New Study" from Forbes.
Additional event context on this page matters because analyst consensus is Buy with a median target of $80.00; recent insider activity includes Green Paula filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
11.87
P/S
13.32
EV/EBITDA
-96.30
DCF Value
$-61.20
FCF Yield
-1.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
52.1%
Operating Margin
-33.9%
Net Margin
-19.8%
ROE
-17.5%
ROA
-12.0%
ROIC
-24.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $110.7M | $-44.0M | $-0.71 |
| Q1 2026 | $103.7M | $-30.5M | $-0.50 |
| Q4 2025 | $99.0M | $-27.1M | $-0.45 |
| FY 2025 | $376.6M | $-77.7M | $-1.30 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$75.00
Target (Median)
$80.00
Target Range
$52.00 - $90.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
2.21
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.